A review of potential pharmacological treatments of COVID-19: an evidence-based perspective

Vikas Kumar, Gyan Vardhan, Kalpana Tiwari, Puneet Dhamija


Coronaviruses (CoVs) typically manifest as mild to severe respiratory tract infections. No drug is approved by US food and drug administration (FDA) for the treatment of patients with coronaviruses infection. With growing COVID-19 pandemic globally, need of hour is to work on potential prophylactic and therapeutic drugs to prevent local and community transmission. A literature search for eligible studies published till March 2020 was conducted in the PubMed, Medline, EMBASE, OVID, and Google Scholar databases by two reviewers. Therapeutic efficacy and safety of different drug regimens targeting treatment pathway acting against corona virus-2019 (COVID-19) were reviewed. Possible mechanism of actions of these potential repurposed drugs against COVID-19 were reviewed to develop effective prevention and treatment strategies. Many potential pharmacological therapies are being studied in various clinical trials. No FDA-approved repurposed drugs have shown safety and efficacy in randomized controlled trials for patients with COVID-19. Vaccines are under development and only few vaccines are under clinical evaluation. This review highlights potential drug actions against COVID-19 and their safety issues. It could help researchers and physicians to use these potential agents judiciously in clinical trials as well as in treatment protocols.


Coronavirus infection, SARS, COVID-19, Pharmacotherapy, Potential Targets, Repurposed Drugs

Full Text:



Zumla A, Chan JFW, Azhar EI, Hui DSC, Yuen KY. Coronaviruses- drug discovery and therapeutic options. Nat Rev Drug Discov. 2016;15(5):327–47.

WHO. Middle East respiratory syndrome coronavirus (MERS-CoV). Available from: emergencies/mers-cov/en. Accessed on 20 March 2020.

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet Lond Engl. 2020;395(10223):507–13.

Bauch CT, Lloyd-Smith JO, Coffee MP, Galvani AP. Dynamically modeling SARS and other newly emerging respiratory illnesses: past, present, and future. Epidemiol Camb Mass. 2005;16(6):791–801.

Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. N Engl J Med. Accessed on 23 March 2020.

CDC. Coronavirus Disease 2019 (COVID-19). Centers for Disease Control and Prevention. 2020. Available from: /2019-ncov/hcp/therapeutic-options.html. Accessed on 23 March 2020.

Prajapat M, Sarma P, Shekhar N, Avti P, Sinha S, Kaur H, et al. Drug targets for corona virus: A systematic review. Ind J Pharmacol. 2020;52(1):56.

Lotteau V, Teyton L, Peleraux A, Nilsson T, Karlsson L, Schmid SL, et al. Intracellular transport of class II MHC molecules directed by invariant chain. Natu. 1990;348(6302):600-5.

Wu SF, Chang CB, Hsu JM, Lu MC, Lai NS, Li C, et al. Hydroxychloroquine inhibits CD154 expression in CD4+ T lymphocytes of systemic lupus erythematosus through NFAT, but not STAT5, signalling. Arthritis research & therapy. 2017;19(1):183.

Dijkmans BA, Verweij CL. Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells. J Rheumatol. 1997;24(1):55-60.

Kužnik A, Benčina M, Švajger U, Jeras M, Rozman B, Jerala R. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol. 2011;186(8):4794-804.

An J, Woodward JJ, Sasaki T, Minie M, Elkon KB. Cutting edge: antimalarial drugs inhibit IFN-β production through blockade of cyclic GMP-AMP synthase–DNA interaction. J Immunol. 2015;194(9):4089-93.

Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antivir Resea. 2020:104787.

Gielen V, Johnston SL, Edwards MR. Azithromycin induces anti-viral responses in bronchial epithelial cells. Europe Respirat J. 2010;36(3):646-54.

Shinkai M, Henke MO, Rubin BK. Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action. Pharmacol Therapeut. 2008;117(3):393-405.

Gautret P, Lagier JC, Parola P, Meddeb L, Mailhe M, Doudier B, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agen. 2020:105949.

Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19 - American College of Cardiology. Available at: gy/articles/2020/03/27/14/00/ventricular-arrhythmia-risk-due-to-hydroxychloroquine-azithromycin-treatment-for-covid-19. Accessed on 16 April 2020.

Xue X, Yu H, Yang H, Xue F, Wu Z, Shen W, et al. Structures of two coronavirus main proteases: implications for substrate binding and antiviral drug design. J Virol. 2008;82(5):2515-27.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engla J Medic. 2020;18.

A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir/Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory Syndrome- Available at: https://clinicaltrials. gov/ct2/show/NCT00578825. Accessed on 16 April 2020.

Welliver R, Monto AS, Carewicz O, Schatteman E, Hassman M, Hedrick J, et al. Oseltamivir Post Exposure Prophylaxis Investigator Group. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. J Americ Medic Assoc. 2001;285(6):748-54.

Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio. 2018;9(2):e00221-18.

A Trial of Remdesivir in Adults with Mild and Moderate COVID-19- Available at: Accessed on 16 April 2020.

Furuta Y, Takahashi K, Kuno-Maekawa M, Sangawa H, Uehara S, Kozaki K, et al. Mechanism of action of T-705 against influenza virus. Antimicrob Agen Chemother. 2005;49(3):981-6.

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lanc. 2020;395(10224):565-74.

Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life scienc. 2020:117477.

Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective Treatment of Severe COVID-19 Patients with Tocilizumab. Chin Xiv prepr. 2020.

Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - Available at: Accessed on 16 April 2020.

Sorrell FJ, Szklarz M, Azeez KR, Elkins JM, Knapp S. Family-wide structural analysis of human numb-associated protein kinases. Struct. 2016;24(3):401-11.

Sallard E, Lescure FX, Yazdanpanah Y, Mentre F, Peiffer-Smadja N, Florence AD, et al. Type 1 interferons as a potential treatment against COVID-19. Antivir Resea. 2020:104791.

Trial of Treatments for COVID-19 in Hospitalized Adult. Available at: show/NCT04315948. Accessed on 16 April 2020.

Biocon Limited. A Multi-Centre, Open Label, Two Arm Randomized, Pivotal Phase 2 Trial to Study the Efficacy and Safety of Itolizumab in COVID-19 Complications. Available at: /ct2/show/NCT04475588. Accessed on 02 July 2020.

Biocon’s Itolizumab Approved in India for COVID-19 Inflammation. Available at: ed-in-india-for-covid19-inflammation. Accessed on 05 July 2020.

Srivastava A. Itolizumab in Psoriasis. Indian J Dermatol. 2017;62(4):418–21.

Loganathan S, Athalye SN, Joshi SR. Itolizumab, an anti-CD6 monoclonal antibody, as a potential treatment for COVID-19 complications. Expert Opin Biol Ther. 2020;1–7.

Chinese Clinical Trial Register (ChiCTR) - The world health organization international clinical trials registered organization registered platform. Available at: Accessed on16 April 2020.

Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis SARS CoV-2 Infection (COVID-19). Available at: https://clinical Accessed on 16 April 2020.

Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine. Available at: 04328441. Accessed on 16 April 2020.

COVAXIN. India’s First Indigenous Covid-19 Vaccine. Bharat Biotech. Available at: Accessed on 7 August 2020.

Bharat Biotech International Ltd. An Adaptive, Seamless Phase 1, Followed by Phase 2 Randomized, Double-blind, Multicentre Study to Evaluate the Safety, Reactogenicity, Tolerability and Immunogenicity of the Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) in Healthy Volunteers. Available at: trials/showallp.php?mid1=45184&EncHid=&userName=bbv152. Last accessed on 10 August 2020.

Kirby T. Development of potential COVID-19 vaccines continues to accelerate. Lancet Microbe. 2020;1(3):e109.

Chugh T. Timelines of COVID-19 Vaccines. Curr Med Res Pract. 2020

Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. J Americ Medic Assoc. 2020.

Hattori A, Migitaka H, Iigo M, Itoh M, Yamamoto K, Ohtani-Kaneko R, et al. Identification of melatonin in plants and its effects on plasma melatonin levels and binding to melatonin receptors in vertebrates. Biochem Mol Biol Int. 1995;35(3):627–34.

Boga JA, Coto-Montes A, Rosales-Corral SA, Tan D-X, Reiter RJ. Beneficial actions of melatonin in the management of viral infections: a new use for this “molecular handyman”? Rev Med Virol. 2012;22(5):323–38.

Results- RECOVERY Trial. Available at: Accessed on 20 June 2020.

Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? The Lanc. Respirat Medic.

Pal R, Bhansali A. COVID-19, Diabetes Mellitus and ACE2: The conundrum. Diabet Resear Clinic Practi. 2020.

Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Resea. 2020;30(3):269-71.

Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinic Infect Diseas. 2020.

Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engla J Medic. 2020.

Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19- Preliminary Report. N Engl J Med. 2020;10.

Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thor. 2004;59(3):252-6.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engla J Medic. 2020.

A Randomized, Open, Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia. Available at: https://clini Accessed on 16 April 2020.

WHO. Blueprint. Priority Disease. Available at: action/Novel_Coronavirus_Landscape_nCoV_PDF. Accessed on 16 April 2020.

FDA. Research C for DE and. Coronavirus Treatment Acceleration Program (CTAP). FDA. Available at: Accessed on 16 April 2020.

Silvestri M, Rossi GA. Melatonin: its possible role in the management of viral infections-a brief review. Itali J Paediat. 2013;39(1):61.

Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Natu. 2020:1-4.

Gitto E, Reiter RJ, Amodio A, Romeo C, Cuzzocrea E, Sabatino G, et al. Early indicators of chronic lung disease in preterm infants with respiratory distress syndrome and their inhibition by melatonin. J Pine Resea. 2004;36(4):250-5.

World Health Organization. WHO welcomes preliminary results about dexamethasone use in treating critically ill COVID-19 patients. Available at: Accessed on 18 June 2020 June.

World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (‎‎‎ nCoV)‎‎‎ infection is suspected. Interim guidance. 2020.